• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Aymen Elfiky, MD, MPH


  • Mahal BA, Ziehr DR, Aizer AA, Hyatt AS, Lago-Hernandez C, Choueiri TK, Elfiky AA, Hu JC, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, Kim SP, Lathan CS, Trinh QD, Nguyen PL.Racial disparities in an aging population: The relationship between age and race in the management of African American men with high-risk prostate cancer.Journal Of Geriatric Oncology. 2014 May 23.
  • Wagle N, Grabiner BC, Van Allen EM, Hodis E, Jacobus S, Supko JG, Stewart M, Choueiri TK, Gandhi L, Cleary JM, Elfiky AA, Taplin ME, Stack EC, Signoretti S, Loda M, Shapiro GI, Sabatini DM, Lander ES, Gabriel SB, Kantoff PW, Garraway LA, Rosenberg JE.Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.Cancer Discovery. 2014 May(5):546-53.
  • Waldman LT, Bean W, Levine AL, Cohen-Bearak A, Phelps FA, Svoboda L, Freedman R, Elfiky A, Berlin S, Abel GA, Deutsch C, Lathan CS.Using FastTrack to Implement an Academic Medical Center and Community Health Center Collaborative for Cancer Care Delivery.Healthcare (Amst). 2013 Dec;1(3-4):130-135.
  • Chen J, Elfiky A, Han M, Chen C, Saif MW.The role of Src in colon cancer and its therapeutic implications.Clin Colorectal Cancer. 2014 Mar;13(1):5-13.
  • Elfiky AA, Jiang Z.The PI3 Kinase Signaling Pathway in Prostate Cancer.Curr Cancer Drug Targets. 2013 Feb 1;13(2):157-64.
  • Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara PN, Lin CC, Srinivas S, Sella A, Schöffski P, Scheffold C, Weitzman AL, Hussain M.Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial.J Clin Oncol. 2012 Nov 19.
  • Nakabayashi M, Werner L, Courtney KD, Buckle G, Oh WK, Bubley GJ, Hayes JH, Weckstein D, Elfiky A, Sims DM, Kantoff PW, Taplin ME.Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer.BJU Int. 2012 Aug 29.
  • Elfiky AA, Sonpavde G.Novel molecular targets for the therapy of renal cell carcinoma.Discov Med. 2012 Jun;13(73):461-71.
  • Elfiky AA, Cho DC, McDermott DF, Rosenberg JE, Fortner B, Antràs L, Chen K, Sheng Duh M, Jayawant SS, Oh WK, Atkins MB, Choueiri TK.Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma.Urol Oncol. 2010 May 5.